PainReform Ltd. — FY2022 Form 20-F
Entity and period: The filing is for PainReform Ltd. (Nasdaq: PRFX), an Israeli clinical-stage pharmaceutical company, for the fiscal year ended December 31, 2022. The request identifies “PRF Technologies Ltd.” and “2022 Q4,” but the filing is PainReform’s annual report, not a standalone fourth-quarter report. Financial statements are in U.S. dollars and prepared under U.S. GAAP.
Business context and outlook
PainReform has no approved products and has never generated revenue. Its lead candidate, PRF-110, is an extended-release formulation of ropivacaine intended to relieve post-surgical pain and reduce opioid use. In March 2023, after the reporting year, the company began its first Phase 3 U.S. trial in bunionectomy patients; a second trial in hernia repair is planned if the first succeeds. These are planned development activities, not established revenue or guidance.
Key financial metrics
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $4.422 million | $2.860 million |
| General and administrative expense | $4.447 million | $4.348 million |
| Operating loss | $8.869 million | $7.208 million |
| Net loss | $8.792 million | $7.246 million |
| Basic and diluted loss per share | $0.82 | $0.74 |
| Net cash used in operating activities | $6.459 million | $6.553 million |
| Cash, cash equivalents and restricted cash at year-end | $4.106 million | $16.571 million |
| Short-term deposits at year-end | $6.085 million | None |
| Current assets / current liabilities | $12.284 million / $1.064 million | $19.020 million / $0.757 million |
| Total liabilities / shareholders’ equity | $1.307 million / $11.021 million | $0.991 million / $18.082 million |
Including short-term deposits and restricted cash, year-end cash resources were approximately $10.2 million; working capital was approximately $11.2 million. The balance sheet reports no material borrowings. Gross margin is not applicable because the company had no revenue. The cash-flow statement shows $6.006 million of investing outflows, primarily a $6.0 million purchase of short-term deposits, and no financing cash inflows in 2022. Accumulated deficit was $32.519 million.
Changes versus the prior year
- Net loss increased by approximately $1.546 million, or 21%, to $8.792 million. R&D expense rose 55%, principally from Phase 3 preparation and higher share-based compensation; G&A increased 2%.
- Operating cash use was broadly stable, decreasing slightly from $6.553 million to $6.459 million. Cash resources including deposits and restricted cash fell from $16.571 million to $10.191 million, with no 2022 financing inflows.
- The company’s FY2022 loss per share increased to $0.82 from $0.74. The weighted-average share count also increased, and 10,634,166 ordinary shares were outstanding at year-end.
Liquidity, risks and unusual items
- Going concern: The independent auditor included a going-concern explanatory paragraph. Management said available resources were expected to fund operations only through Q4 2023, while the financial statements also say funds were insufficient to support operations through completion of the Phase 3 study. The company expects to seek additional equity, debt or strategic-partner funding; none was committed in the filing. Failure to obtain financing could force reductions or cessation of operations.
- Clinical and manufacturing risks: Manufacturing issues delayed the Phase 3 launch, though the company reported resolving them and completing process validation. It relies on third-party manufacturers and a single source for some critical materials. Trial success, enrollment, regulatory approval, manufacturing compliance and commercialization remain uncertain.
- Contract commitments: The contractual-obligations table lists $11.218 million for clinical research and trial agreements. The notes describe subsequently negotiated agreement totals of $5.568 million and $8.636 million, respectively, which do not reconcile to that table; verify the current committed amounts and payment timing.
- Internal controls and fraud incident: A 2022 supplier-impersonation incident led to a $165,000 fraudulent payment; most was recovered, with an immaterial unrecovered amount reserved. Management said it remediated the identified weakness and concluded internal control over financial reporting was effective at year-end. The auditor did not attest to controls, consistent with the company’s emerging-growth-company exemption.
- Nasdaq listing: The company received a minimum-bid-price deficiency notice in August 2022 and a second compliance period through August 7, 2023. Delisting remained a risk if it did not regain compliance.
- Other risks: The filing highlights substantial future funding needs, dependence on PRF-110, competition, intellectual-property and third-party execution risks, geopolitical and security conditions in Israel, foreign-exchange exposure, and possible capital-market disruption. The company does not intend to pay dividends for the foreseeable future.
- Equity compensation: In November 2022, the company cancelled 667,641 options and issued 988,773 replacement options, including grants to a new employee, on revised terms. Share-based compensation expense was $1.731 million in 2022.
Important facts for investors to verify
- Whether PainReform secured financing after the filing date, and its current cash runway and operating burn.
- Progress, enrollment, safety and efficacy results for the Phase 3 bunionectomy trial, and the timing and funding of the planned hernia-repair trial.
- Reconciliation of the $11.218 million contractual-obligations table with the updated CRO agreement amounts described in the notes.
- Current Nasdaq listing status and any subsequent share issuance, financing or dilution.
- Whether the supplier-payment control remediation is operating effectively and whether any portion of the $165,000 loss remains unrecovered.